Uncategorized

The company agreed to buy a diabetes health business and medical supplier Strive Medical to boost its growing in-home solutions unit.

The computing platform will make its debut at the Society of Robotic Surgery meeting this week, as Medtronic challenges Intuitive in the U.S. robotic soft tissue market.

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”

The deal is the latest in a series of pacts with health systems, including with Sutter Health and UC San Diego.

Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.

The biopharma industry would do well to re-embrace the 505(b)(2) path, which allows sponsors to draw on previous findings around an existing drug even as they propose modifications to it.

Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma’s second quarter earnings call—though major pickups aren’t completely off the table.

Axiom Biosciences is thinking outside of the box, betting on a public debut in Hong Kong to raise capital and grow into a global company.

If approved, Dyne Therapeutics’ zeleciment rostudirsen could “capture the majority” of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Therapeutics’ exon-skipping therapy Exondys 51, the current standard of care, according to Oppenheimer.

  Por Sebastien Leroux, nutricionista especializado en micronutrición y fundador de APONA   Como fundador de una marca de suplementación, tengo un interés directo en este mercado. Lo digo desde el principio porque me parece más honesto que ocultarlo: este a …